CN114980865A - 一种棕榈酸帕利哌酮混悬液的制备方法 - Google Patents

一种棕榈酸帕利哌酮混悬液的制备方法 Download PDF

Info

Publication number
CN114980865A
CN114980865A CN202080080880.1A CN202080080880A CN114980865A CN 114980865 A CN114980865 A CN 114980865A CN 202080080880 A CN202080080880 A CN 202080080880A CN 114980865 A CN114980865 A CN 114980865A
Authority
CN
China
Prior art keywords
pressure
bar
cycling
value selected
polyethylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080080880.1A
Other languages
English (en)
Other versions
CN114980865B (zh
Inventor
钱桦江
蒋钰
赵振坤
陈叶明
许向阳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Enhua Biomedical Technology Co ltd
Nhwa Pharmaceutical Corp
Original Assignee
Suzhou Enhua Biomedical Technology Co ltd
Nhwa Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Enhua Biomedical Technology Co ltd, Nhwa Pharmaceutical Corp filed Critical Suzhou Enhua Biomedical Technology Co ltd
Publication of CN114980865A publication Critical patent/CN114980865A/zh
Application granted granted Critical
Publication of CN114980865B publication Critical patent/CN114980865B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

一种棕榈酸帕利哌酮混悬液的制备方法，其采用活塞狭缝式高压均质法制备得到棕榈酸帕利哌酮混悬液，所得到的混悬液具有适宜的粒径分布，可以发挥理想缓释作用。

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN202080080880.1A 2019-11-29 2020-11-27 一种棕榈酸帕利哌酮混悬液的制备方法 Active CN114980865B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019111998832 2019-11-29
CN201911199883 2019-11-29
PCT/CN2020/132287 WO2021104460A1 (zh) 2019-11-29 2020-11-27 一种棕榈酸帕利哌酮混悬液的制备方法

Publications (2)

Publication Number Publication Date
CN114980865A true CN114980865A (zh) 2022-08-30
CN114980865B CN114980865B (zh) 2023-07-21

Family

ID=76129156

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080080880.1A Active CN114980865B (zh) 2019-11-29 2020-11-27 一种棕榈酸帕利哌酮混悬液的制备方法

Country Status (2)

Country Link
CN (1) CN114980865B (zh)
WO (1) WO2021104460A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116444516A (zh) * 2023-03-20 2023-07-18 济宁学院 棕榈酸帕利哌酮纳米晶体及其制备方法、棕榈酸帕利哌酮纳米晶混悬注射液及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102525915A (zh) * 2010-12-14 2012-07-04 江苏豪森医药集团有限公司 一种持续释放的注射制剂及其制备方法和用途
CN104906038A (zh) * 2015-06-24 2015-09-16 万特制药(海南)有限公司 一种阿立哌唑纳米晶体及其制备方法
CN105012236A (zh) * 2015-08-10 2015-11-04 深圳市泛谷药业有限公司 一种长效非水载体注射液及其制备方法
CN105816425A (zh) * 2016-04-15 2016-08-03 沈阳药科大学 一种制备纳米混悬液的前处理方法
CN106137985A (zh) * 2016-08-04 2016-11-23 齐鲁制药有限公司 一种稳定的棕榈酸帕利哌酮长效制剂
CN107281100A (zh) * 2016-03-30 2017-10-24 上海现代药物制剂工程研究中心有限公司 一种难溶性药物纳米混悬液的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009026621A1 (en) * 2007-08-29 2009-03-05 Alphapharm Pty Ltd Pharmaceutical compound & composition
AU2010278601A1 (en) * 2009-07-31 2012-02-23 Xi'an Libang Medical Technology Co., Ltd Nanosphere or microsphere drug carrier, preparation method, composition and use thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102525915A (zh) * 2010-12-14 2012-07-04 江苏豪森医药集团有限公司 一种持续释放的注射制剂及其制备方法和用途
CN104906038A (zh) * 2015-06-24 2015-09-16 万特制药(海南)有限公司 一种阿立哌唑纳米晶体及其制备方法
CN105012236A (zh) * 2015-08-10 2015-11-04 深圳市泛谷药业有限公司 一种长效非水载体注射液及其制备方法
CN107281100A (zh) * 2016-03-30 2017-10-24 上海现代药物制剂工程研究中心有限公司 一种难溶性药物纳米混悬液的制备方法
CN105816425A (zh) * 2016-04-15 2016-08-03 沈阳药科大学 一种制备纳米混悬液的前处理方法
CN106137985A (zh) * 2016-08-04 2016-11-23 齐鲁制药有限公司 一种稳定的棕榈酸帕利哌酮长效制剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PIDAPARTHI,KARTIKA等: "Comparison of Nanoemulsion and Aqueous Micelle Systems of Paliperidone for Intranasal Delivery" *
ZIWEI MA等: "Development and evaluation of intramuscularly administered nano/microcrystal suspension" *

Also Published As

Publication number Publication date
CN114980865B (zh) 2023-07-21
WO2021104460A1 (zh) 2021-06-03

Similar Documents

Publication Publication Date Title
Sawicki et al. Inventory of oral anticancer agents: Pharmaceutical formulation aspects with focus on the solid dispersion technique
EP2477608B1 (en) Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
CN108261394B (zh) 一种盐酸卡利拉嗪注射制剂及其制备方法和用途
EP2229936B1 (en) Nanonized testosterone formulations for improved bioavailability
CN103211759B (zh) 葛根素纳米晶药用组合物及其制备方法
Kim et al. Fabrication and evaluation of valsartan–polymer–surfactant composite nanoparticles by using the supercritical antisolvent process
EP2868315A1 (en) Improved formulations and methods for lyophilization and lyophilates provided thereby
NO332844B1 (no) Oral doseringsform inneholdende en PDE4-hemmer som aktivt ingrediens og polyvinylpyrrolidon som eksipiens, anvendelse derav og fremgangsmåte for fremstilling av det samme.
EP2768485B1 (en) Pharmaceutical nanosuspension
EP3838265A1 (en) Injectable pharmaceutical composition and preparation method therefor
CN104906038A (zh) 一种阿立哌唑纳米晶体及其制备方法
CN114980865A (zh) 一种棕榈酸帕利哌酮混悬液的制备方法
CN111110646A (zh) 一种低规格醋酸阿比特龙口服制剂的处方及制备方法
WO2014003677A1 (en) Pharmaceutical compositions comprising solid dispersion particles containing tadalafil
US20060013871A1 (en) Intimate coating of ibuprofen with poloxamers to enhance aqueous dissolution
Shi et al. Progress in the study of drug nanocrystals
CN104415034B (zh) 一种咪达那新药物组合物及其制备方法
US20220395514A1 (en) Low-dose celecoxib preparation
EP4178540A1 (en) Long-acting formulations
CN103159710B (zh) 用于抗病毒的十氢萘衍生物
CN103655571A (zh) 一种洛匹那韦和利托那韦复方高均匀度纳米共分散体及其制备方法
CN113440529B (zh) 一种可注射的药物组合物及其制备方法
CN111440086A (zh) 曲尼司特的盐
CN115887406B (zh) 一种克唑替尼胶囊的制备方法
CN117771222B (zh) 一种雷芬那辛吸入喷雾剂及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: 215021 Building 6, Tengfei Innovation Park, No. 388, Xinping Street, Suzhou Industrial Park, Jiangsu Province

Applicant after: Suzhou Enhua Biomedical Technology Co.,Ltd.

Applicant after: NHWA PHARMA. Corp.

Address before: 221000 No.18, Yangshan Road, Xuzhou Economic Development Zone, Jiangsu Province

Applicant before: NHWA PHARMA. Corp.

Applicant before: Suzhou Enhua Biomedical Technology Co.,Ltd.

GR01 Patent grant
GR01 Patent grant